Transcriptome analyses using homozygous TP53-mutated myeloid malignancy cell lines and primary AML/myelodysplastic syndrome (MDS) patient samples have demonstrated that even low doses of eprenetapropt can reactivate the p53 pathway and apoptotic programs when administered in combination with a HMA [68]. Here, TP53 is linked to myelodysplastic syndrome.